# Angiotensin 2 for Hepatorenal Syndrome

> **NCT04048707** · PHASE2 · WITHDRAWN · sponsor: **University of California, Los Angeles**

## Conditions studied

- Hepatorenal Syndrome
- Cirrhosis
- Kidney Failure, Acute

## Interventions

- **DRUG:** Angiotensin II
- **DRUG:** Midodrine
- **DRUG:** Octreotide
- **DRUG:** Albumin solution

## Key facts

- **NCT ID:** NCT04048707
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding issues; the study was never started
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04048707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04048707, "Angiotensin 2 for Hepatorenal Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04048707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*